Ev3 Atherectomy Biz Stabilizing After Sales Force Improvements, Firm Says
This article was originally published in The Gray Sheet
Executive Summary
Ev3 believes a sales force restructuring initiated earlier this year is bearing fruit for its struggling atherectomy business
You may also be interested in...
ev3 Expands Neurovascular Division With Acquisition Of Chestnut
ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2
Ev3’s Atherectomy Business On The Upswing After Troubled First Quarter
Endovascular device firm ev3's formerly rocky marriage with FoxHollow is now on steadier ground with a better-than-expected recovery of its atherectomy business in the second quarter
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.